45 results about "Intergenic region" patented technology

The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

The present invention relates to detection of pathogenic mycobacteria in clinical specimens such as sputum, cerebrospinal fluid, gastric lavage and tissue biopsies etc., wherein the novel stretch of DNA that lies in the intergenic region between methyl mycolic acid synthase genes mmaA1 and mmaA2 and the flanking region in mmaA1 and mmaA2 genes and is the invention uses a pair of designed oligonucleotide primers that specifically amplifies the target DNA from the clinical specimens.

The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.

The present invention relates to a microarray comprising a chimeric probe for an intergenic exon-to-exon junction of a fusion gene and at least two intragenic probes for a fusion gene partner of the fusion gene. The invention further relates to a method of detecting a fusion gene and a kit suitable for detecting fusion genes.

The invention provides a tubercle bacillus drug tolerance detection reagent kit and method. The tubercle bacillus drug tolerance detection reagent kit comprises a tubercle bacillus drug tolerance detection reagent, wherein the tubercle bacillus drug tolerance detection reagent comprises a sequencing primer in accordance with a tubercle bacillus drug tolerance gene; the tubercle bacillus drug tolerance gene comprises one or more genes of rpoB, katG, inhA-promoter, inhA-structural, furA, embB, ubiA, pncA, rpsA, gyrA, gyrB, eis, rpsL, rrs, tlyA, rplC and rrl; and further, the reagent kit also contains a tubercle bacillus nucleic acid detection reagent, and the tubercle bacillus nucleic acid detection reagent comprises a primer pair 1 in accordance with IS6110, a primer pair 2 in accordance with the IS6110 and a probe primer in accordance with the IS6110. Through the adoption of the tubercle bacillus drug tolerance detection reagent kit disclosed by the invention, tubercle bacillus nucleicacid in samples can be quickly detected, and positive samples can be further subjected to drug tolerance detection; and the tubercle bacillus drug tolerance detection reagent kit has good sensitivity, good specificity and good accuracy, and can perform mutation detection on 48 sites of 17 drug tolerance genes of common antituberculosis drugs and fragment deficiency detection of an intergenic region, so that the tuberculosis medication can be more accurately and comprehensively guided.

The invention provides an improved PCR detection method of the dwarfing bacteria of sugarcane persistent roots. A pair of specific primers Lxx1 / Lxx2 are designed according to an RSD pathogenic bacterium Lxx 16S-23SrDNA intergenic region nucleotide sequence, and a PCR multiplication method is adopted to detect the dwarfing bacteria of sugarcane persistent roots after the improved method is used for extracting the total DNA of sugarcane juice; the method overcomes the defects of the prior detection technique; and the invention provides the PCR detection method of the dwarfing bacteria of the sugarcane persistent roots, which has the advantages of high speed, stability, accuracy, high sensitivity and strong specificity.

The invention discloses a new mutation site related to isoniazide resistance of mycobacterium tuberculosis and an application thereof. The new mutation site is positioned at a 1673425th site of a standard strain H37Rv genome, that is a 126th base in an intergenic region of Rv1482c to Rv1483*, and the generated point mutation comprises that a base C is mutated into a base T or a base A. The found new mutation site can be used as a detection target applied in detection of the isoniazide resistance of mycobacterium tuberculosis, improves the molecular detection level of the isoniazide resistance of mycobacterium tuberculosis, shortens the diagnosis time of patients, and saves the treating time and cost for the patients. The mycobacterium tuberculosis drug-resistant mutation site is explained to possibly occur in a non-coding region, the base mutation of the intergenic region is prompted to be possibly related to the drug resistance, and a drug-resistant biomarker also exists. The invention provides a new idea for finding out a new and more effective mycobacterium tuberculosis drug-resistant molecular marker.

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

Intergenic non-coding RNA molecules that regulate the expression of HWP1 and ALS3 of Candida are provided as are methods of using the non-coding RNA molecules and complementary molecules thereof in modulating HWP1 or ALS3 expression; adherence, yeast-to-hyphal transition, or biofilm development of Candida; and preventing or treating candidiasis.

The invention relates to a method for identifying honeysuckle and lonicera confuse and an application of the method. The method disclosed by the invention comprises the step of performing PCR (polymerase chain reaction) amplification on ITS2 nucleotide sequence, and particularly comprises the steps of 1) extracting the DNA (deoxyribonucleic acid) of a sample; 2) performing PCR amplification on the segments of the ITS2 sequence containing ribosome DNA; 3) splicing the amplification products to obtain a complete ITS2 intergenic region; and 4) establishing the NJ (neighbour-joining) tree of the ITS2 sequence of the sample. The method disclosed by the invention can be used for effectively solving the problems of variety identification, variety improvement and breeding of honeysuckle medicinal materials, development and utilization of germplasm resources, and the like; and the method disclosed by the invention is wide in applicability, simple to operate, easy to grasp, high in accuracy, and capable of successfully realizing rapid and accurate identification on honeysuckle medicinal materials or powder and lonicera confuse medicinal materials or powder.

The invention relates to the field of biotechnology, and discloses an efficient and controllable expression system of an exogenous gene carried by an endogenous source, which includes a sequentially connected sequence: a host target gene stop codon upstream segment containing a stop codon, and a fungal operon gene interval region, the target gene, and the DNA fragment downstream of the stop codon of the host target gene, the target gene is connected using the fungal operon intergenic region sequence, and inserted into the downstream of the stop codon of the host cell expression gene by site-directed gene insertion. The promoter of the target gene completes the transcriptional expression of the target gene. The expression system simplifies the experimental operation steps, improves work efficiency, increases the controllability and stability of target gene expression, and reduces the requirement for known promoter diversity for multi-gene heterologous expression. The excavation of natural products, the improvement of production and the creation of unnatural compounds have high practical application value.

A method for the high level production of active, properly processed recombinant protein in trans-splicing organisms is disclosed. The method involves the integration of the gene encoding the recombinant protein of interest into a chromosomal locus where it is transcribed under the direction of the rRNA promoter. The gene is also operably linked to intergenic regions allowing the protein to be translated in these organisms. The recombinant organisms expressing a therapeutic protein can also be used to treat a disease or undesirable condition which is characterized by a deficiency in that protein.

This invention relates to a method for stably expressing a transgene integrated into the genome of an animal cell or of an animal over a long period. Specifically, this invention provides: an approximately 2.5 kb XhoI-BamHI fragment (or XB fragment) derived from the Evx2-Hoxd13 intergenic region of the animal genome, or a homologue thereof; a DNA containing a foreign DNA wherein the DNA has been inserted between the two essentially identical XB fragments or homologues thereof; a vector, animal cell, or nonhuman mammalian animal containing said DNA; and use of the vector, animal cell, or nonhuman mammalian animal for production of a substance or therapy.